Shares of clinical-stage biotech company NeuroSense Therapeutics Ltd (NASDAQ:NRSN) are ripping higher Thursday morning after the company reported positive final results from its Alzheimer’s biomarker study.
What Happened: Preliminary results from a study evaluating the potential of NeuroSense’s combination platform therapy for the treatment of Alzheimer’s disease (AD), showed that TDP-43, a novel biomarker, was elevated in AD patients compared to a healthy control group.
Based on the “encouraging” results, NeuroSense has expanded the study with a larger healthy control group to further validate the preliminary reading.
NeuroSense’s platform combination therapy technology has already shown a statistically significant reduction of TDP-43 in a Phase 2a clinical trial biomarker study in amyotrophic lateral sclerosis (ALS), and is currently being evaluated in a Phase 2b ALS double-blind clinical trial.
NeuroSense believes its preliminary results suggest the potential efficacy of NeuroSense’s platform technology in Alzheimer’s disease. The company said it plans to start a Phase 2 double-blind proof-of-concept study in Alzheimer’s disease in the first half of 2023.
NeuroSense is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases.
Check This Out: Best Biotech Stocks Right Now
NRSN Price Action: NeuroSense has a 52-week high of $8.18 and a 52-week low of $1.07.
The stock was up 73.8% at $2.19 at the time of writing, according to Benzinga Pro.
Photo: Alexandra_Koch from Pixabay.
